Flavopiridol-induced iNOS downregulation during apoptosis of chronic lymphocytic leukemia cells is caspase-dependent

Leukemia Research

Volumn 32, Issue 5, 2008, Pages 755-760

  Billard, Christian ^a   Menasria, Faouzia ^a   Quiney, Claire ^a   Faussat, Anne Marie ^a   Kolb, Jean Pierre ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Apoptosis; Cell cycle; CLL; Flavopiridol; iNOS; p27kip1

Indexed keywords

CASPASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FLAVOPIRIDOL; INDUCIBLE NITRIC OXIDE SYNTHASE;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL CYCLE PHASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRIORITY JOURNAL;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL CYCLE; CELLS, CULTURED; DOWN-REGULATION; FLAVONOIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NITRIC OXIDE SYNTHASE TYPE II; PIPERIDINES;

EID: 40049090335     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.09.016     Document Type: Article

References (31)

1. Byrd J.C., Lin T.S., and Grever M.R. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies. Semin Oncol 33 (2006) 210-219
2. Kolb J.P., Kern C., Quiney C., Roman V., and Billard C. Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Current Drug Targets Cardiovasc Hematol Disord 3 (2003) 261-286
3. Grever M.R., Lucas D.M., Dewald G.W., Neuberg D.S., Reed J.C., Kitada S., et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup phase III trial E2997. J Clin Oncol 25 (2007) 799-804
4. Byrd J.C., Shinn C., Waselenko J.K., Fuchs E.J., Lehman T.A., Nguyen P.L., et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92 (1998) 3804-3816
5. Senderowicz A.M. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 15 (2001) 1-9
6. Lin T.S., and Porcu P. Flavopiridol: where do we stand in chronic lymphocytic leukemia?. Leukemia 18 (2004) 243-246
7. Grever M.D., Lucas D.M., Johnson A.J., and Byrd J.C. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20 (2007) 545-556
8. Billard C., Kern C., Tang R., Ajchenbaum-Cymbalista F., and Kolb J.P. Flavopiridol downregulates the expression of both the inducible NO synthase and p27kip1 in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 17 (2003) 2345-2443
9. Zhao H., Dugas N., Mathiot C., Dugas B., Sigaux F., and Kolb J.P. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 92 (1998) 1031-1043
10. Vrhorac R., Delmer A., Tang R., Marie J.P., Zittoun R., and Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27kip1 in chronic lymphocytic leukemia. Blood 91 (1998) 4694-4700
11. Kolb J.P. Mechanisms involved in the pro- and anti-apoptotic effects of NO in human leukemia. Leukemia 4 (2000) 1685-1694
12. Roman V., Zhao H., Fourneau J.M., Marconi A., Dugas N., Dugas B., et al. Expression of a functional inducible nitric oxide synthase in hairy cell leukemia and Eskol cell line. Leukemia 14 (2000) 696-705
13. Harvey W., Srour E.F., Turner R., Carey R., Maze R., Starrett B., et al. Characterization of a new cell line (ESKOL) resembling hairy-cell leulemia: a model for oncogene regulation and late B-cell differentiation. Leukemia Res 15 (1991) 733-744
14. Roman V., Billard C., Kern C., Ferry-Dumazet H., Izard J.C., Mohammad R., et al. Analysis of resveratrol-induced apoptosis in human B-cell chronic leukemia. Br J Haematol 117 (2002) 842-851
15. Billard C., Izard J.C., Roman V., Kern C., Mathiot C., Mentz F., et al. Comparative antiproliferative and apoptotic effects of resveratrol, ε-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal lymphocytes. Leuk Lymphoma 43 (2002) 1991-2002
16. Quiney C., Dauzonne D., Kern C., Fourneron J.D., Mohammad R.M., Izard J.C., et al. Flavones and polyphenols inhibit the NO pathway during apoptosis of leukemia B-cells. Leukemia Res 28 (2004) 851-861
17. Fourneron J.D., and Naït-Si Y. Effect of eluent pH on hplc/uv analysis of hyperforin. Phytochem Anal 17 (2006) 71-77
18. Bailly C., Bal C., Barbier P., Combes S., Finet J.P., Hidebrand M.P., et al. Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. J Med Chem 46 (2003) 5437-5444
19. Quiney C., Billard C., Faussat A.M., Salanoubat C., Ensaf A., Fourneron J.D., et al. Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Leukemia 20 (2006) 491-497
20. Frost V., and Sinclair A.J. P27kip1 is down-regulated by two different mechanisms in human lymphoid cells undergoing apoptosis. Oncogene 19 (2000) 115-3120
21. Li J., Billiar T.R., Talanian R.V., and Kim Y.M. Nitric oxid reversely inhibits seven members of the caspase family via S-nitrosylation. Biochem Biophys Res Commun 240 (1995) 419-424
22. Dimmeler S., Haendeler J., Nehls M., and Zeiher A.M. Suppression of apoptosis by nitric oxid via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease (CCP)-32-like proteases. J Exp Med 185 (1997) 601-607
23. Mannick J.B., Hausladen A., Liu L., Hess D.T., Zeng M., Miao Q.X., et al. Fas-induced caspase denitrosylation. Science 284 (1999) 651-654
24. Azad N., Vallyatan V., Wang L., Tantishaiyakul V., Stehlik C., Leonard S.S., et al. S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteosomal degradation: a novel mechanism that suppresses apoptosis. J Biol Chem 281 (2006) 34124-34134
25. Tiscornia A.C., Cayota A., Landoni A.I., Brito C., Oppezzo P., Vuiller F., et al. Post-transcriptional regulation of inducible nitric oxide synthase in chronic lymphocytic leukemia B cells in pro- and antiapoptotic culture conditions. Leukemia 18 (2004) 48-56
26. Kolodziejki P.J., Musial A., Koo J.S., and Eissa N.T. Ubiquitination of inducible nitric oxide synthase is required for its degradation. Proc Natl Acad Sci 99 (2002) 12315-12320
27. Byrd J.C., Peterson B.L., Gabrilove J., Odenike O.M., Grever M.R., Rai K., et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 11 (2005) 4176-4181
28. Flinn I.W., Byrd J.C., Bartlett N., Kipps T., Gribben J., Thomas D., et al. Flavopiridol admistered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leukemia Res 29 (2005) 1253-1257
29. Byrd J.C., Lin T.S., Dalton J.T., Wu D., Phelps M.A., Fischer B., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109 (2007) 399-404
30. Karp J.E., Ross D.D., Yang W., Tidwell M.L., Wei Y., Greer J., et al. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for phase I clinical trial. Clin Cancer Res 9 (2003) 307-315
31. Karp J.E., Smith B.D., Levis M.J., Gore S.D., Greer J., Hattenburg C., et al. Sequential flavopiridol, cytosine arabinoside and mitoxanthrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 13 (2007) 4467-4473